...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Reports of Exempt Distribution

Koo,,,agreed,,,, but,,it works both ways,,,with the expected irrational exuberance that markets tend to produce we just cant seem to make the grade. It is generally thought that the OTC market values a company more than it should be due to the unknown unknowns,,,,and investing institutions claim the investors could be taken advantage of due to less than transparent busines and the creative asccounting along with it.,,!

Share
New Message
Please login to post a reply